NeuroCatch

NeuroCatch operates at the intersection of medical devices, neuroscience, and digital health. Its NeuroCatch® Platform is differentiated by an objective, EEG-based assessment that measures event-related potentials and is designed to be used at the point of care in about six minutes. The company describes the system as assessing auditory sensation, basic attention, and cognitive processing, and its first medical device is licensed by Health Canada as a Class II medical device. This places its offering closer to clinical assessment equipment and research tools than to general wellness applications, although its partnerships also extend into sports performance and military research. The useful basis for positioning is therefore its stated approach: rapid physiological measurement intended to add objective information alongside other assessments, not replace them or serve as a standalone diagnosis. NeuroCatch is privately held and is a wholly owned subsidiary of HealthTech Connex.

Founded in 2015, NeuroCatch has developed around one core product: the NeuroCatch® Platform, an EEG-based system for rapid brain-function assessment. The company’s description says the platform is licensed by Health Canada as a Class II medical device and is intended for healthcare practitioners, researchers, and performance specialists. Its activity suggests an effort to apply the technology across several settings. The Nov 28, 2024 Gwin Racing partnership introduced the Elevate program in downhill mountain biking; the Aug 14, 2025 Lovell partnership targeted federal healthcare providers; and the May 12, 2026 agreement with The Geneva Foundation focused on military cognitive health research. These are identifiable commercial and research milestones, but the announcements do not establish the scale or results of implementation. The company is listed in an 11–50 employee band, and it has expressed an intention to add approximately 10 employees over the first three years at a new U.S. headquarters in Phoenix, with the hiring period’s start date unspecified.